1Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6.

2Less JR, Skalak TC, Sevick EM, Jain RK (1991) Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 51: 265-273.

3Sharma S, Sharma MC, Sarkar C (2005) Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology 46: 481-489.

4Kimura H, Braun RD, Ong ET, Hsu R, Secomb TW, et al. (1996) Fluctuations in red cell flux in tumor microvessels can lead to temporary hypoxia and reoxygenation in tumor parenchyma. Cancer Res 56: 5522-5528.

5Gillies RJ, Schornack PA, Secomb TW, Raghunand N (1999) Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1: 197-207.

6Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26: 638-648.

7 Vaupel P (2004) The role of hypoxia-induced factors in tumor progression. The Oncologist 9(Suppl. 5), 10-17.

8Vaupel P (2008) Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. The Oncologist 13: 21-26.

9Wood JE, Litter J, Wilkins RW (1955) The mechanism of limb segment reactive hyperemia in man. Circ Res 3: 581-587.

10Marcus M, Wright C, Doty D, Eastham C, Laughlin D, et al. (1981) Measurements of coronary velocity and reactive hyperemia in the coronary circulation of humans. Circ Res 49: 877-891.

11Cohnheim J (1872) Untersuchungen ueber die embolische Processe. Berlin, A. Hirschwald.

12Suzuki M, Hori K, Abe I, Saito S, Sato H (1981) A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 67: 663-669.

13Peterson HI (1991) Modification of tumour blood flow-a review. Int J Radiat Biol 60: 201-210.

14 Sonveaux P, Jordan BF, Gallez B, Feron O (2009) Nitric oxide delivery to cancer: why and how? Eur J Cancer 45: 1352-1369.

15Reyal J (2010) How could a Basic Knowledge of Vascular Physiology provide a New Tool for Tumor Oxygen-induced Radiosensitization- Postocclusive Reactive Hyperemia Concept for Synchronized Radiotherapy. WebmedCentral CANCER 1: WMC00604.

16Reyal J, Lebas N, Fourme E, Guihard T, Vilmer C, et al. (2012) Post-occlusive reactive hyperemia in basal cell carcinoma and its potential application to improve the efficacy of solid tumor therapies. Tohoku J Exp Med 227: 139-147.

17Pettan-Brewer C, Morton J, Coil R, Hopkins H, Fatemie S, et al. (2012) B16 melanoma tumor growth is delayed in mice in an age-dependent manner. Pathobiol Aging Age Relat Dis 2.

18Roustit M, Millet C, Blaise S, Dufournet B, Cracowski JL (2010) Excellent reproducibility of laser speckle contrast imaging to assess skin microvascular reactivity. Microvasc Res 80: 505-511.

19Baudelet C, Gallez B (2004) Effect of anesthesia on the signal intensity in tumors using BOLD-MRI: comparison with flow measurements by Laser Doppler flowmetry and oxygen measurements by luminescence-based probes. Magn Reson Imaging 22: 905-912.

20Wen B, Urano M, O'Donoghue JA, Ling CC (2006) Measurements of partial oxygen pressure pO2 using the OxyLite system in R3327-AT tumors under isoflurane anesthesia. Radiat Res 166: 512-518.

21Stücker M, Springer C, Paech V, Hermes N, Hoffmann M, et al. (2006) Increased laser Doppler flow in skin tumors corresponds to elevated vessel density and reactive hyperemia. Skin Res Technol 12: 1-6.

22Hill SA, Pigott KH, Saunders MI, Powell ME, Arnold S, et al. (1996) Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. Br J Cancer Suppl 27: S260-263.

23Ellingsen C, Ovrebø KM, Galappathi K, Mathiesen B, Rofstad EK (2012) pO2 fluctuation pattern and cycling hypoxia in human cervical carcinoma and melanoma xenografts. Int J Radiat Oncol Biol Phys 83: 1317-1323.

24Helfrich I, Scheffrahn I, Bartling S, Weis J, von Felbert V, et al. (2010) Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 207: 491-503.

25 Suzuki S, Heldin CH, Heuchel RL (2007) Platelet-derived growth factor receptor-beta, carrying the activating mutation D849N, accelerates the establishment of B16 melanoma. BMC Cancer 7: 224.